Reviva Virtual Annual Meeting of Stockholders: Day of Meeting Information
Nov 10, 2022 at 2:00 PM EST
To join the meeting please go to this link: www.virtualshareholdermeeting.com/RVPH2022 and join as a “guest”.
Reviva is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva’s pipeline currently includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both RP5063 and RP1208 in the United States (U.S.), Europe, and several other countries.